Clinical Trial: FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06403111) titled 'FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC' on April 27.

Brief Summary: This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine first-line standard therapy to enhance the anti-tumor immune effect at the same time, thereby extending the progression-free survival of patients and improving the prognosis of patients.

Study Type: Interventional

Condition: Non-small Cell Lung Cancer

Intervention: Combination Product: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy

Participants received FMT combined with tisle...